Novanta Inc Stock Price, News & Analysis

Novanta (Nasdaq: NOVT) announced a public offering of 11,000,000 tangible equity units with an aggregate stated amount of $550.0 million; each unit has a stated amount of $50.00 and comprises a prepaid stock purchase contract and a senior amortizing note due 2028. Novanta has applied to list the units on Nasdaq under NOVTU and granted underwriters a 30-day option to buy up to 1,650,000 additional units to cover over-allotments.

Net proceeds are expected to be used to strengthen the balance sheet and enhance strategic flexibility, including a planned repayment of approximately $317 million under the revolving credit facility and for working capital, acquisitions, capex, share repurchases and general corporate purposes.

Novanta (Nasdaq: NOVT) reported Q3 2025 results on November 3, 2025: GAAP revenue $247.8M (+1.4% YoY) and GAAP net income $10.7M with GAAP diluted EPS $0.30. Non-GAAP results included Adjusted EBITDA $58.1M and Adjusted diluted EPS $0.87. Bookings grew 17% YoY with book-to-bill of 1.03x. Q3 operating cash flow was $8.5M, down from $23.0M a year earlier. For Q4 2025 Novanta expects revenue of $253M–$257M; full-year 2025 revenue guidance is $975M–$979M. The company reiterated product-driven growth and provided 2026 mid-single-digit organic growth expectations.

Novanta (Nasdaq: NOVT) announced that Matthijs Glastra, Chair & Chief Executive Officer, is scheduled to present at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025 in London.

The presentation provides an investor-facing update and a scheduled public appearance by senior management at a major healthcare investor conference.

Novanta (Nasdaq: NOVT) will host an ISO working group event on humanoid robot safety standards in Barcelona, Spain, from October 27–30, 2025. The multi-year ISO initiative aims to define a global safety framework for designing, developing, and deploying humanoid robots, including safe human/robot interaction in real-world environments.

The session will gather 40–50 international experts to advance the proposed international standard ISO 25785-1. Hosting the event highlights Novanta's stated commitment to collaborative innovation and advancing safety-first practices for physical AI and humanoid robotics.

Novanta (Nasdaq: NOVT) announced that Matthijs Glastra, Chair & Chief Executive Officer, is scheduled to present at the Baird 2025 Global Industrial Conference on Tuesday, November 11, 2025 in Chicago, Illinois.

Investors can expect management representation at the conference on that date; details on timing and access were not provided in this announcement.

Novanta (Nasdaq: NOVT) will release its third quarter 2025 results on Tuesday, November 4, 2025. A conference call to discuss results is scheduled for 8:30 a.m. ET the same day.

Investors may join by phone at (888) 346-3959 or listen via a live webcast on the company’s Investors & Events page at www.novanta.com. An audio replay will be posted about three hours after the call and will remain available through Monday, December 29, 2025.

Novanta Inc. (Nasdaq: NOVT), a medical and advanced technology equipment manufacturer partner, has announced a significant expansion of its share repurchase program. The company's Board of Directors has authorized an additional $200 million for share repurchases, which adds to the existing $31 million remaining from its 2020 authorization, bringing the total capacity to $231 million.

The repurchase program has no time limit and will be funded through cash on hand and future cash flows. Shares may be purchased discretionally through various methods, including accelerated share purchase agreements, open market transactions, or private negotiations. The company maintains flexibility to suspend or discontinue the program at any time while emphasizing its commitment to both shareholder returns and strategic growth investments.

Novanta (Nasdaq: NOVT), a trusted technology partner to medical and advanced technology equipment manufacturers, has announced its participation in the upcoming Baird 2025 Global Healthcare Conference. Matthijs Glastra, Chair & Chief Executive Officer, and Robert Buckley, Chief Financial Officer, will represent the company at the conference, which will take place on September 9, 2025, in New York, NY.

Novanta (Nasdaq: NOVT) reported its Q2 2025 financial results with revenue increasing 2.2% to $241.0 million. The company posted GAAP net income of $4.5 million and diluted EPS of $0.12, down from $13.8 million and $0.38 respectively in Q2 2024.

Key highlights include 10% growth in bookings and a book-to-bill ratio of 1.02. The Advanced Surgery and Robotics & Automation businesses achieved mid-teens revenue growth. The company secured significant design wins in medical devices and warehouse robotics sectors.

For full-year 2025, Novanta updated guidance to revenue of $970-985 million, Adjusted EBITDA of $225-230 million, and Adjusted EPS of $3.22-3.36. Q3 2025 revenue is expected at $244-247 million.